If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug...
Hence then, the article about pdufa action date for hansa biopharma s imlifidase bla set for december 19 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026 )
Also on site :
- Police called to multiple central Ohio schools after alleged bomb threats
- Decagon completes first tender offer at $4.5B valuation
- Live Nation DOJ Trial, Lil Durk Delay, Justin Timberlake Lawsuit & More Top Music Law News